Frontier Biotechnologies Inc. Class A

As of June 30, 2026, Frontier Biotechnologies Inc. Class A carries a market capitalization of 8.39B, placing it among publicly traded companies globally. Its enterprise value stands at 8.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Frontier Biotechnologies Inc. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Frontier Biotechnologies Inc. Class A has 374.58M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Frontier Biotechnologies Inc. Class A maintains a current ratio of 4.96, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Frontier Biotechnologies Inc. Class A's stock has declined approximately 5.94% over the past 52 weeks. The 50-day moving average sits at 17.55, while the 200-day moving average is 20.46.

As of June 30, 2026, Frontier Biotechnologies Inc. Class A holds 711.08M in cash and equivalents against 419.42M in total debt, resulting in a net debt position of 11.79M. Total book value stands at 1.03B, with working capital of 952.75M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Frontier Biotechnologies Inc. Class A paid dividends of 0.02 per share.